SotalolCAS# 3930-20-9 |
- B-Raf inhibitor 1 dihydrochloride
Catalog No.:BCC4183
CAS No.:1191385-19-9
- Axitinib (AG 013736)
Catalog No.:BCC3729
CAS No.:319460-85-0
- SB590885
Catalog No.:BCC4392
CAS No.:405554-55-4
- Vandetanib (ZD6474)
Catalog No.:BCC3883
CAS No.:443913-73-3
- Sorafenib Tosylate
Catalog No.:BCC3654
CAS No.:475207-59-1
- Brivanib Alaninate (BMS-582664)
Catalog No.:BCC1240
CAS No.:649735-63-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 3930-20-9 | SDF | Download SDF |
| PubChem ID | 5253 | Appearance | Powder |
| Formula | C12H20N2O3S | M.Wt | 272.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| Chemical Name | N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide | ||
| SMILES | CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O | ||
| Standard InChIKey | ZBMZVLHSJCTVON-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Sotalol Dilution Calculator
Sotalol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.6711 mL | 18.3554 mL | 36.7107 mL | 73.4214 mL | 91.7768 mL |
| 5 mM | 0.7342 mL | 3.6711 mL | 7.3421 mL | 14.6843 mL | 18.3554 mL |
| 10 mM | 0.3671 mL | 1.8355 mL | 3.6711 mL | 7.3421 mL | 9.1777 mL |
| 50 mM | 0.0734 mL | 0.3671 mL | 0.7342 mL | 1.4684 mL | 1.8355 mL |
| 100 mM | 0.0367 mL | 0.1836 mL | 0.3671 mL | 0.7342 mL | 0.9178 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Sotalol Hydrochloride is an adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
- Ginsenoside Compound K
Catalog No.:BCN1246
CAS No.:39262-14-1
- Oxyresveratrol 2-O-beta-D-glucopyranoside
Catalog No.:BCN1448
CAS No.:392274-22-5
- (E)-Cinnamyl-(Z)-p-coumarate
Catalog No.:BCN7694
CAS No.:391682-51-2
- Ac-His-OH.H2O
Catalog No.:BCC2953
CAS No.:39145-52-3
- Trimebutine
Catalog No.:BCC4615
CAS No.:39133-31-8
- N-Me-Ala-OH.HCl
Catalog No.:BCC2619
CAS No.:3913-67-5
- PD0325901
Catalog No.:BCC1277
CAS No.:391210-10-9
- PD318088
Catalog No.:BCC2539
CAS No.:391210-00-7
- Nigranoic acid
Catalog No.:BCN2399
CAS No.:39111-07-4
- Ajmalan-17-one
Catalog No.:BCN3519
CAS No.:3911-19-1
- Karakoline
Catalog No.:BCC8331
CAS No.:39089-30-0
- UCM 707
Catalog No.:BCC7217
CAS No.:390824-20-1
- Tiplaxtinin(PAI-039)
Catalog No.:BCC6439
CAS No.:393105-53-8
- 2,3-Dihydroxy-4-methoxybenzoic acid
Catalog No.:BCN6534
CAS No.:3934-81-4
- BCTC
Catalog No.:BCC7797
CAS No.:393514-24-4
- Neurotensin
Catalog No.:BCC5842
CAS No.:39379-15-2
- Kamebanin
Catalog No.:BCN5449
CAS No.:39388-57-3
- Ethyl 3,4-dihydroxybenzoate
Catalog No.:BCN8504
CAS No.:3943-89-3
- Eleutheroside E
Catalog No.:BCN1083
CAS No.:39432-56-9
- Boceprevir
Catalog No.:BCC1435
CAS No.:394730-60-0
- 3-Acetylcoumarin
Catalog No.:BCC8603
CAS No.:3949-36-8
- CC-401
Catalog No.:BCC4269
CAS No.:395104-30-0
- Sinigrin
Catalog No.:BCN8484
CAS No.:3952-98-5
- Asperosaponin VI
Catalog No.:BCN1256
CAS No.:39524-08-8
Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children.[Pubmed:28283175]
Am J Cardiol. 2017 May 1;119(9):1366-1370.
Our objective was to evaluate the efficacy and safety of intravenous (IV) Sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function. Eighty-three children admitted to hospital from October 2011 to December 2014 were treated with IV Sotalol or IV Sotalol plus IV propafenone. The time to conversion to sinus rhythm and maintaining sinus rhythm were evaluated. Blood pressure, heart rate, QTc, PR intervals, and rhythm were monitored; 50 patients (60%) were converted to sinus rhythm with IV Sotalol; time to conversion was 12.0 +/- 18.0 hours; 12 additional patients (15%) were converted with IV Sotalol combined with IV propafenone; time to conversion was 13.1 +/- 17.6 hours. A total of 62 patients (75%) were converted. Success rates of IV Sotalol for different tachycardias were similar, whereas the time to conversion differed. The time to conversion for atrioventricular reentrant tachycardia was shorter than atrial tachycardia or atrial flutter (p <0.05). QTc prolongation (from 253 to 486 ms and from 398 ms to 500 ms) was seen in 2 patients (2%) within 48 hours after conversion. The QTc reverted to normal range at 48 and 144 hours, respectively, after withdrawal of IV Sotalol. A 1 month old with atrial flutter developed bradycardia (7:1 atrioventricular conduction) 5 minutes after IV Sotalol, and heart rate increased gradually after drug withdrawal. No other adverse effects were observed. In conclusion, IV Sotalol can be safely and effectively used to terminate pediatric tachycardias in patients with normal cardiac function. No proarrhythmic or significant toxicities were detected. Close monitoring of QTc and heart rate is required after IV Sotalol. Adding IV propafenone to IV Sotalol in resistant cases enhance conversion.
Sotalol versus Amiodarone in Treatment of Atrial Fibrillation.[Pubmed:27909477]
J Atr Fibrillation. 2016 Feb 29;8(5):1359.
The availability of intravenous (IV) Sotalol has equalized the treatment options since both amiodarone and Sotalol are available in both IV and oral formulations. A review of the efficacy of Sotalol as compared to amiodarone both for conversion of atrial fibrillation (AF) and maintenance of normal sinus rhythm (NSR) following cardiac surgery was undertaken. Standard methods of meta-analysis were employed. Full text publications of clinical trials written in English that compared the efficacy of Sotalol to amiodarone were included in the analysis. For the conversion of AF to NSR, five studies were found eligible for the analysis. Two studies clinically compared Sotalol to amiodarone for the maintenance of NSR after cardiac surgery. The common relative success of Sotalol was 0.947 (95Cl: 0.837 to 1.071, P = 0.385), revealing essentially no differences in efficacy for conversion between amiodarone and Sotalol. The average conversion rate was 47% with Sotalol and 52% with amiodarone. The conversion rates were lower for persistent AF (Sotalol 22% and amiodarone 27%), while greatest for recent onset AF (88% Sotalol and 77% for amiodarone). The risk of developing post-operative atrial fibrillation was practically the same in both regimes, relative risk = 1.214 (95% CI: 0.815-1.808, p=0.339). In summary, Sotalol and amiodarone are equally effective in AF conversion and maintenance of NSR post-cardiac surgery.
Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis.[Pubmed:27554842]
Cardiology. 2017;136(1):52-60.
OBJECTIVES: The role of Sotalol is well established for the maintenance of sinus rhythm after successful conversion of atrial fibrillation (AF). However, its role in pharmacologic conversion of AF is poorly defined. The purpose of this study is to compare the efficacy of Sotalol to that of other antiarrhythmic agents for AF conversion. METHODS: Standard methods of meta-analysis were employed. Full-text publications of clinical trials in English that compared the efficacy of Sotalol to that of other antiarrhythmics or placebo/no treatment were eligible for inclusion. RESULTS: A systematic review revealed 10 eligible publications. Sotalol was superior to placebo and/or no antiarrhythmic therapy in AF conversion, with a relative success of 24 (95% CI 4.7-119, p < 0.001). Sotalol was not significantly different from class IA antiarrhythmic drugs. Similarly, Sotalol was not different from class IC antiarrhythmic drugs or amiodarone in terms of conversion efficacy. In one study, Sotalol was less effective than high-dose ibutilide (2 mg), with a relative success of 0.248 (95% CI 0.128-0.481, p < 0.001). Ibutilide caused more proarrhythmia. CONCLUSIONS: Sotalol is as effective as class IA and class IC antiarrhythmic agents, and it is also as effective as amiodarone for pharmacologic conversion of AF. Only ibutilide at a high dose showed a greater conversion rate of AF.
Does Sotalol Still Have a Role in the Management of Arrhythmias?[Pubmed:27759583]
Am J Ther. 2019 Jan/Feb;26(1):e161-e169.
Despite proven effectiveness in treating tachyarrhythmias, Sotalol is proarrhythmic and can cause torsades de pointes. Given the emergence of studies that show no benefit from rhythm control strategies in managing atrial fibrillation, as well as the introduction of nonpharmacological approaches to treating arrhythmias, we felt it necessary to ascertain if there was any role for Sotalol given its side effects. Review of the literature regarding Sotalol use in the prevention and treatment of supraventricular and ventricular tachyarrhythmias seems to show that more effective and safer agents and nonpharmacological alternatives are currently available. However, Sotalol still seems to be useful in preventing supraventricular tachyarrhythmias postcardiac surgery and in reverting hemodynamically stable sustained ventricular tachycardias in the setting of coronary artery disease. Its role in the prevention of tachyarrhythmias in the setting of arrhythmogenic right ventricular cardiomyopathy requires further investigation.
